Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate
To evaluate the feasibility of using a biodegradable intrascleral implant for intraocular sustained delivery of betamethasone phosphate (BP). The intrascleral implant (0.5 mm thick and 4 mm in diameter) was made of poly(DL-lactide) containing 25% betamethasone phosphate. The in vitro release of BP f...
Gespeichert in:
| Veröffentlicht in: | Investigative ophthalmology & visual science 2003-02, Vol.44 (2), p.740 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 740 |
| container_title | Investigative ophthalmology & visual science |
| container_volume | 44 |
| creator | Okabe, Junko Kimura, Hideya Kunou, Noriyuki Okabe, Komei Kato, Aki Ogura, Yuichiro |
| description | To evaluate the feasibility of using a biodegradable intrascleral implant for intraocular sustained delivery of betamethasone phosphate (BP).
The intrascleral implant (0.5 mm thick and 4 mm in diameter) was made of poly(DL-lactide) containing 25% betamethasone phosphate. The in vitro release of BP from the implant was evaluated by high-performance liquid chromatography (HPLC). The implants were placed into a scleral pocket in the rabbit's eye. The concentrations of BP in the aqueous humor, vitreous, and retina-choroid were measured by HPLC. The toxicity and biocompatibility of the implant were evaluated by slit lamp examination, electroretinography, and light microscopy.
In vitro studies demonstrated that the implants released BP in a biphasic pattern for at least 8 weeks. The BP concentrations in the vitreous and the retina-choroid remained within the concentration range capable of suppressing inflammatory responses for more than 8 weeks. The BP concentration was greater in the retina-choroid than in the vitreous. In the aqueous humor, BP was below the detection limit during the observation period. No significant toxicity to the retina was observed. Also, the implant showed good biocompatibility in the eye.
These results suggest that the intrascleral implant would be a promising system for delivery of steroid to the posterior segment of the eye. |
| doi_str_mv | 10.1167/iovs.02-0375 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_12556407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12556407</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-46fee0fe19b31ef99c90a1925f9f00729df7f22effea61552d707504b964ed523</originalsourceid><addsrcrecordid>eNo1j7FOwzAUAD2AaClszMg_kPLs2LE8QgUUqRILzOWlfqZGThzZbqX-PUNhuuV00jF2J2ApRGceQjqWJcgGWqMv2ByE6hpQoGbsupQfACmEhCs2E1LrToGZs6-nkBx9Z3TYR-JhrBnLLlLGyMMwRRwr9ynzcigVw0jurKTdIWLmjmI4Uj7x5HlPFQeqeyxpJD7tU5n2WOmGXXqMhW7_uGCfL88fq3WzeX99Wz1umkm0tjaq80TgSdi-FeSt3VlAYaX21gMYaZ03XkrynrATWktnwGhQve0UOS3bBbs_d6dDP5DbTjkMmE_b_9X2F9nAVn0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Okabe, Junko ; Kimura, Hideya ; Kunou, Noriyuki ; Okabe, Komei ; Kato, Aki ; Ogura, Yuichiro</creator><creatorcontrib>Okabe, Junko ; Kimura, Hideya ; Kunou, Noriyuki ; Okabe, Komei ; Kato, Aki ; Ogura, Yuichiro</creatorcontrib><description>To evaluate the feasibility of using a biodegradable intrascleral implant for intraocular sustained delivery of betamethasone phosphate (BP).
The intrascleral implant (0.5 mm thick and 4 mm in diameter) was made of poly(DL-lactide) containing 25% betamethasone phosphate. The in vitro release of BP from the implant was evaluated by high-performance liquid chromatography (HPLC). The implants were placed into a scleral pocket in the rabbit's eye. The concentrations of BP in the aqueous humor, vitreous, and retina-choroid were measured by HPLC. The toxicity and biocompatibility of the implant were evaluated by slit lamp examination, electroretinography, and light microscopy.
In vitro studies demonstrated that the implants released BP in a biphasic pattern for at least 8 weeks. The BP concentrations in the vitreous and the retina-choroid remained within the concentration range capable of suppressing inflammatory responses for more than 8 weeks. The BP concentration was greater in the retina-choroid than in the vitreous. In the aqueous humor, BP was below the detection limit during the observation period. No significant toxicity to the retina was observed. Also, the implant showed good biocompatibility in the eye.
These results suggest that the intrascleral implant would be a promising system for delivery of steroid to the posterior segment of the eye.</description><identifier>ISSN: 0146-0404</identifier><identifier>DOI: 10.1167/iovs.02-0375</identifier><identifier>PMID: 12556407</identifier><language>eng</language><publisher>United States</publisher><subject>Absorbable Implants ; Animals ; Aqueous Humor - metabolism ; Betamethasone - administration & dosage ; Betamethasone - analogs & derivatives ; Betamethasone - pharmacokinetics ; Choroid - metabolism ; Chromatography, High Pressure Liquid ; Delayed-Action Preparations ; Drug Delivery Systems ; Drug Implants ; Electroretinography ; Feasibility Studies ; Glucocorticoids - administration & dosage ; Glucocorticoids - pharmacokinetics ; Polyesters ; Rabbits ; Retina - metabolism ; Sclera - drug effects ; Vitreous Body - metabolism</subject><ispartof>Investigative ophthalmology & visual science, 2003-02, Vol.44 (2), p.740</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12556407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okabe, Junko</creatorcontrib><creatorcontrib>Kimura, Hideya</creatorcontrib><creatorcontrib>Kunou, Noriyuki</creatorcontrib><creatorcontrib>Okabe, Komei</creatorcontrib><creatorcontrib>Kato, Aki</creatorcontrib><creatorcontrib>Ogura, Yuichiro</creatorcontrib><title>Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate</title><title>Investigative ophthalmology & visual science</title><addtitle>Invest Ophthalmol Vis Sci</addtitle><description>To evaluate the feasibility of using a biodegradable intrascleral implant for intraocular sustained delivery of betamethasone phosphate (BP).
The intrascleral implant (0.5 mm thick and 4 mm in diameter) was made of poly(DL-lactide) containing 25% betamethasone phosphate. The in vitro release of BP from the implant was evaluated by high-performance liquid chromatography (HPLC). The implants were placed into a scleral pocket in the rabbit's eye. The concentrations of BP in the aqueous humor, vitreous, and retina-choroid were measured by HPLC. The toxicity and biocompatibility of the implant were evaluated by slit lamp examination, electroretinography, and light microscopy.
In vitro studies demonstrated that the implants released BP in a biphasic pattern for at least 8 weeks. The BP concentrations in the vitreous and the retina-choroid remained within the concentration range capable of suppressing inflammatory responses for more than 8 weeks. The BP concentration was greater in the retina-choroid than in the vitreous. In the aqueous humor, BP was below the detection limit during the observation period. No significant toxicity to the retina was observed. Also, the implant showed good biocompatibility in the eye.
These results suggest that the intrascleral implant would be a promising system for delivery of steroid to the posterior segment of the eye.</description><subject>Absorbable Implants</subject><subject>Animals</subject><subject>Aqueous Humor - metabolism</subject><subject>Betamethasone - administration & dosage</subject><subject>Betamethasone - analogs & derivatives</subject><subject>Betamethasone - pharmacokinetics</subject><subject>Choroid - metabolism</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Delayed-Action Preparations</subject><subject>Drug Delivery Systems</subject><subject>Drug Implants</subject><subject>Electroretinography</subject><subject>Feasibility Studies</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - pharmacokinetics</subject><subject>Polyesters</subject><subject>Rabbits</subject><subject>Retina - metabolism</subject><subject>Sclera - drug effects</subject><subject>Vitreous Body - metabolism</subject><issn>0146-0404</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j7FOwzAUAD2AaClszMg_kPLs2LE8QgUUqRILzOWlfqZGThzZbqX-PUNhuuV00jF2J2ApRGceQjqWJcgGWqMv2ByE6hpQoGbsupQfACmEhCs2E1LrToGZs6-nkBx9Z3TYR-JhrBnLLlLGyMMwRRwr9ynzcigVw0jurKTdIWLmjmI4Uj7x5HlPFQeqeyxpJD7tU5n2WOmGXXqMhW7_uGCfL88fq3WzeX99Wz1umkm0tjaq80TgSdi-FeSt3VlAYaX21gMYaZ03XkrynrATWktnwGhQve0UOS3bBbs_d6dDP5DbTjkMmE_b_9X2F9nAVn0</recordid><startdate>200302</startdate><enddate>200302</enddate><creator>Okabe, Junko</creator><creator>Kimura, Hideya</creator><creator>Kunou, Noriyuki</creator><creator>Okabe, Komei</creator><creator>Kato, Aki</creator><creator>Ogura, Yuichiro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200302</creationdate><title>Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate</title><author>Okabe, Junko ; Kimura, Hideya ; Kunou, Noriyuki ; Okabe, Komei ; Kato, Aki ; Ogura, Yuichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-46fee0fe19b31ef99c90a1925f9f00729df7f22effea61552d707504b964ed523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Absorbable Implants</topic><topic>Animals</topic><topic>Aqueous Humor - metabolism</topic><topic>Betamethasone - administration & dosage</topic><topic>Betamethasone - analogs & derivatives</topic><topic>Betamethasone - pharmacokinetics</topic><topic>Choroid - metabolism</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Delayed-Action Preparations</topic><topic>Drug Delivery Systems</topic><topic>Drug Implants</topic><topic>Electroretinography</topic><topic>Feasibility Studies</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - pharmacokinetics</topic><topic>Polyesters</topic><topic>Rabbits</topic><topic>Retina - metabolism</topic><topic>Sclera - drug effects</topic><topic>Vitreous Body - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okabe, Junko</creatorcontrib><creatorcontrib>Kimura, Hideya</creatorcontrib><creatorcontrib>Kunou, Noriyuki</creatorcontrib><creatorcontrib>Okabe, Komei</creatorcontrib><creatorcontrib>Kato, Aki</creatorcontrib><creatorcontrib>Ogura, Yuichiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Investigative ophthalmology & visual science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okabe, Junko</au><au>Kimura, Hideya</au><au>Kunou, Noriyuki</au><au>Okabe, Komei</au><au>Kato, Aki</au><au>Ogura, Yuichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate</atitle><jtitle>Investigative ophthalmology & visual science</jtitle><addtitle>Invest Ophthalmol Vis Sci</addtitle><date>2003-02</date><risdate>2003</risdate><volume>44</volume><issue>2</issue><spage>740</spage><pages>740-</pages><issn>0146-0404</issn><abstract>To evaluate the feasibility of using a biodegradable intrascleral implant for intraocular sustained delivery of betamethasone phosphate (BP).
The intrascleral implant (0.5 mm thick and 4 mm in diameter) was made of poly(DL-lactide) containing 25% betamethasone phosphate. The in vitro release of BP from the implant was evaluated by high-performance liquid chromatography (HPLC). The implants were placed into a scleral pocket in the rabbit's eye. The concentrations of BP in the aqueous humor, vitreous, and retina-choroid were measured by HPLC. The toxicity and biocompatibility of the implant were evaluated by slit lamp examination, electroretinography, and light microscopy.
In vitro studies demonstrated that the implants released BP in a biphasic pattern for at least 8 weeks. The BP concentrations in the vitreous and the retina-choroid remained within the concentration range capable of suppressing inflammatory responses for more than 8 weeks. The BP concentration was greater in the retina-choroid than in the vitreous. In the aqueous humor, BP was below the detection limit during the observation period. No significant toxicity to the retina was observed. Also, the implant showed good biocompatibility in the eye.
These results suggest that the intrascleral implant would be a promising system for delivery of steroid to the posterior segment of the eye.</abstract><cop>United States</cop><pmid>12556407</pmid><doi>10.1167/iovs.02-0375</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-0404 |
| ispartof | Investigative ophthalmology & visual science, 2003-02, Vol.44 (2), p.740 |
| issn | 0146-0404 |
| language | eng |
| recordid | cdi_pubmed_primary_12556407 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Absorbable Implants Animals Aqueous Humor - metabolism Betamethasone - administration & dosage Betamethasone - analogs & derivatives Betamethasone - pharmacokinetics Choroid - metabolism Chromatography, High Pressure Liquid Delayed-Action Preparations Drug Delivery Systems Drug Implants Electroretinography Feasibility Studies Glucocorticoids - administration & dosage Glucocorticoids - pharmacokinetics Polyesters Rabbits Retina - metabolism Sclera - drug effects Vitreous Body - metabolism |
| title | Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A48%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biodegradable%20intrascleral%20implant%20for%20sustained%20intraocular%20delivery%20of%20betamethasone%20phosphate&rft.jtitle=Investigative%20ophthalmology%20&%20visual%20science&rft.au=Okabe,%20Junko&rft.date=2003-02&rft.volume=44&rft.issue=2&rft.spage=740&rft.pages=740-&rft.issn=0146-0404&rft_id=info:doi/10.1167/iovs.02-0375&rft_dat=%3Cpubmed%3E12556407%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12556407&rfr_iscdi=true |